ERBB2 and neoplasm: Specifically, we aimed to gain insights on whether there is evidence of unfavourable pathological features (tumour histology, pathological tumour size, nodal involvement, distant metastasis, tumour grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status) among women with common comorbid conditions.